Compare MNDY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDY | PRAX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 9.6B |
| IPO Year | 2021 | 2020 |
| Metric | MNDY | PRAX |
|---|---|---|
| Price | $75.72 | $301.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 15 |
| Target Price | $174.92 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 3.0M | 328.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.70 | N/A |
| Revenue Next Year | $16.48 | $6,395.88 |
| P/E Ratio | $34.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $68.68 | $26.70 |
| 52 Week High | $316.98 | $354.87 |
| Indicator | MNDY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 39.85 |
| Support Level | $68.80 | $290.36 |
| Resistance Level | $79.30 | $322.32 |
| Average True Range (ATR) | 4.09 | 17.69 |
| MACD | 2.68 | -5.16 |
| Stochastic Oscillator | 53.26 | 14.99 |
Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.